Kiadis Pharma N.V.. (3/13/18). "Press Release: Kiadis Pharma Raises €23.4 Million in a Private Placement of 2.6 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction in which Unlawful]". Amsterdam.

	Organisation	Kiadis Pharma N.V. (Euronext: KDS)
	Group	Kiadis (Group)
	Organisation 2	Jefferies International Ltd.
	Group	Leucadia (Group)
	Product	ATIR101™ (Kiadis)
	Product 2	investment banking
	Index term	Kiadis–SEVERAL: investment, 201803 private placement €23.4m w 2.6m new shares €9/share to institutional investors
	Person	Lahr, Arthur (Kiadis 201704– CEO before Crucell 200701 Chief Strategy Officer + EP Sales + BusDev)
	Person 2	Hård, Karl (Kiadis 201709– Head IR + Communications before Redx Pharma 201610– Head of IR + CorpComm before AstraZeneca)

Original document
accessed by [iito] on 2018-03-28

Record changed: 2018-03-31

More documents for Kiadis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

» top

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Kiadis Pharma N.V.. (3/13/18). "Press Release: Kiadis Pharma Raises €23.4 Million in a Private Placement of 2.6 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction in which Unlawful]". Amsterdam.

More documents for Kiadis (Group)